logo

Reata Pharmaceuticals, Inc. (RETA)



Trade RETA now with
  Date
  Headline
10/10/2019 6:55:57 AM Reata Reacquires Rights From AbbVie To Develop Bardoxolone Methyl, Omaveloxolone, Next-Generation Nrf2 Activators
2/28/2019 6:51:30 AM Reata Pharma Q4 Net Loss $25.6 Mln Or $0.86/Shr Vs Loss $16.7 Mln Or $0.64/shr Last Year
1/7/2019 7:16:17 AM Reata Pharmaceuticals Appoints Geoffrey Block VP, Nephrology
11/7/2018 7:20:09 AM Reata Pharma Q3 Net Loss $30.8 Mln Or $1.07/shr Vs. Net Loss $12.3 Mln Or $0.50/shr Last Year
7/24/2018 9:16:16 PM Reata Pharma Announces Pricing Of Offering Of 3 Mln Shares Of Class A Common Stock At $72.00/shr
7/23/2018 4:40:15 PM Reata Pharmaceuticals Announces Proposed Public Offering Of Class A Common Stock
7/23/2018 6:52:29 AM Reata Announces Results From Two Phase 2 Studies Of Bardoxolone Methyl In Chronic Kidney Disease Patients
6/14/2018 4:31:09 PM Reata Pharmaceuticals Secures $125 Mln Term Loan Facility
6/4/2018 7:35:43 AM Reata Pharma Says Kyowa Hakko Kirin Initiated Ayame, A Phase 3 Trial Of Bardoxolone Methyl For Diabetic Kidney Disease
5/25/2018 5:51:14 AM Will PHOENIX Make RETA Fly?
  
 
>